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009: Systems Medicine, Transformational Technologies
and the Emergence of Predictive, Personalized,
Preventive and Participatory (P4) Medicine
Leroy Hood
Institute of Systems Biology, Seattle, WA, United States of America
The challenge for biology in the twenty first century is the need to
deal with its incredible complexity. One powerful way to think of
biology is to view it as an informational science. This view leads to
the conclusion that biological information is captured, mined, inte-
grated and finally executed by biological networks. Hence the
challenge in understanding biological complexity is that of deci-
phering the operation of dynamic biological networks across the three
time scales of life-evolution, development and physiological
responses. Systems approaches to biology are focused on delineating
and deciphering dynamic biological networks and their interactions
with simple and complex molecular machines. I will focus on our
efforts at a systems approach to disease-looking at prion disease and
cancer. I will also discuss the emerging technologies (measurement
and visualization) that will transform medicine over the next 10 years.
It appears that systems medicine, together with pioneering changes in
DNA sequencing and blood protein measurements (nanotechnology)
and as well as the development of powerful new computational and
mathematical tools will transform medicine over the next 5–20 years
from its currently reactive state to a mode that is predictive, per-
sonalized, preventive and participatory (P4). This will in turn lead to
the digitalization of medicine-with ultimately a profound decrease in
the cost of healthcare. It will also transform the business strategies for
virtually every sector of the health care industry. These considerations
have led ISB to begin formulating a series of national and interna-
tional strategic partnerships that are focused on making P4 medicine a
reality. I will discuss some of these strategic partnerships and discuss
the implications arising from the globalization of science.
010: A robustness-based approach to systems-oriented
drug design
Hiroaki Kitano
The Systems Biology Institute, 6A M31 6-31-15 Jingumae, Shibuya,
Tokyo, Japan
Many potential drugs that specifically target a particular protein
considered to underlie a given disease have been found to be less
effective than hoped, or to cause significant side effects. The intrinsic
robustness of living systems against various perturbations is a key
factor that prevents such compounds from being successful. By
studying complex network systems and reformulating control and
communication theories that are well established in engineering, a
theoretical foundation for a systems-oriented approach to more
effectively control the robustness of living systems, particularly at the
cellular level, could be developed. Here, I use examples that are based
on existing drugs to illustrate the concept of robustness, and then
discuss how a greater consideration of the importance of robustness
could influence the design of new drugs that will be intended to
control complex systems.
011: Information processing by the intracellular
signaling network
Kanury Rao
International Centre for Genetic Engineering and Biotechnology,
Aruna Asaf Ali Marg, New Delhi 110067, India
The coordinated response of a cell to environmental cues such as
growth factors and hormones is mediated through the activation of
various signal transduction pathways. Our current perception of sig-
naling pathways is that they constitute a highly complex network that,
like most other complex networks, exhibits a scale-free topology.
Consequently, the functional outcome of signal transduction would
likely represent the integrated result of the intricate and varied
interactions between the numerous individual constituents of the
network. While overall topology of the signaling network has been
revealed, mechanisms that regulate the pathways embedded within
this network continue to remain enigmatic. For instance, the question
of how the amplitude and rate of signal transfer are modulated is yet
unclear. Stimulation of a given cell surface receptor with different
agonists is known to evoke diverse cellular responses, although they
all activate the same intracellular pathways. This is especially true in
the case of lymphocytes, where variations in the nature of antigen
receptor triggering can lead to the opposing and extreme outcomes of
cell death on the one hand, to proliferation and differentiation on the
other. While such observations point to the inherent plasticity of
signaling networks, how this is achieved remains to be clarified.
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Studies from our laboratory suggest that, during the process of signal
transduction, the individual components of the network exhibit cha-
otic behavior. As a result, transmission of signal through the modules
of the network occurs in a non-synchronized manner. Importantly, it
is this feature of asynchronic transmission that provides the opera-
tional framework for signal processing in a combinatorial manner and
thus accounts for the plasticity of the signaling network.
012: The $10 Million Dollar Archon X PRIZE
in Genomics
Larry Kedes1,2
1Institute for Genetic Medicine, University of Southern California,
2250 Alcazar St. Los Angeles, CA, 90089, United States of America,
2X PRIZE Foundation, 1441 4th Street, Suite 200 Santa Monica,
CA 90401, United States of America
Incentive prizes for technological breakthroughs have a long history
of successfully advancing science and engineering. The X PRIZE
Foundation has lead the way in creating a series of incentive prizes
that will result in innovations that makes a lasting impact. Although a
technological breakthrough can meet this criterion, so do prizes which
inspire teams to use existing technologies, knowledge or systems in
more effective ways? As scientists gain knowledge from mapping the
Human Genome, they will also find new ways to treat and even
prevent disease. To build the library of information necessary to
advance the field of genomic medicine, it is imperative that we
develop DNA sequencing technology that is faster and affordable. To
stimulate breakthrough innovation in the field of genomic sequencing
and to help lay the groundwork for the era of personalized medicine,
the X PRIZE Foundation has launched a global competition with a
$10 million (USD) prize for the winner of the Archon X PRIZE for
Genomics. The $10 million X PRIZE for Genomics prize purse will
be awarded to the first non-governmental Team that can develop a
system and use it
• to sequence 100 human genomes
• within 10 days or less
• with an accuracy of no more than one error in every 100,000 bases
• with sequences accurately covering at least 98% of the reference
genome
• with complete Haplotype information
• at a recurring cost of no more than $10,000 per genome.
The presentation will discuss the current teams in the competition,
the rationale for the winning criteria, and the ways in which the X
PRIZE Foundation is developing methods to deal with judging of the
contest, validation of data and ensuring ethical standards for the
individuals whose DNA is involved in the contest.
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